PLX 7486

Drug Profile

PLX 7486

Alternative Names: PLX-7486; PLX7486-TsOH

Latest Information Update: 18 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Plexxikon
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Fms-like tyrosine kinase 3 inhibitors; TrkA receptor antagonists; TrkB receptor antagonists; TrkC receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pancreatic cancer; Solid tumours

Most Recent Events

  • 18 Apr 2016 Phase I development is ongoing in USA
  • 01 Aug 2013 Phase-I clinical trials in Solid tumours & Pancreatic cancer (late-stage disease, second-line therapy or greater) in USA (PO)
  • 03 Jun 2013 Plexxikon files an IND application with the US FDA for PLX 7486 for Solid tumours
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top